Omeros gets regulatory clearance to begin Phase 1 clinical trial of OMS721

Omeros Corporation (NASDAQ: OMER) today announced that it has obtained regulatory clearance to start the Phase 1 clinical trial evaluating OMS721, the Company's lead human monoclonal antibody from its mannan-binding lectin-associated serine protease-2 (MASP-2) program. The first clinical trial with OMS721 will be conducted in Europe and will evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of OMS721 administered subcutaneously in healthy subjects. Omeros plans to follow this study with a clinical trial evaluating OMS721 in patients with atypical hemolytic uremic syndrome (aHUS), a rare but life-threatening form of thrombotic microangiopathy (TMA). Enrollment in the initial clinical trial is scheduled to begin next month.

Omeros has filed for orphan drug designation in the United States for the use of OMS721 to treat aHUS and will request orphan drug designation in Europe as well. Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2.

OMS721 selectively inhibits MASP-2, a novel pro-inflammatory protein involved in activation of the complement system, which is an important component of the immune system and plays a role in the inflammatory response to tissue damage or microbial infection. By selectively inhibiting MASP-2, OMS721 blocks the lectin pathway of the complement system while leaving intact the classical pathway, which represents the acquired immune response to infection.

Omeros' previously reported preclinical findings indicate that blockade of MASP-2 by OMS721 may have a preventive or therapeutic effect in the treatment of aHUS and other life-threatening TMAs, such as hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, as well as a wide range of additional disorders, including age-related macular degeneration, ischemia-reperfusion injury and transplant-related complications.

"We are pleased that the European regulatory authorities have cleared the way for us to evaluate the potential of OMS721 in humans," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The lectin pathway appears to play an important role across a wide range of serious disorders. The preclinical data for OMS721 are strong, and we continue to drive the clinical development of the antibody."

Source:

Omeros Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Matcha green tea enhances cognition and sleep in older adults